{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:50:53Z","timestamp":1776408653092,"version":"3.51.2"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06782-y","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T02:38:13Z","timestamp":1771209493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synergistic adverse prognostic impact of CD30 and Epstein\u2013Barr virus in peripheral T-cell lymphoma: CD30 identifies a high-risk subgroup in Epstein\u2013Barr virus\u2013encoded RNA -positive patients"],"prefix":"10.1007","volume":"105","author":[{"given":"Ze-Tao","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Miao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Juan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Guo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cai-Di","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei-Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Chu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhan-Li","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"6782_CR1","doi-asserted-by":"crossref","unstructured":"Yoon SE, Song Y, Kim SJ, Yoon DH, Chen TY, Koh Y et al (2021) Comprehensive analysis of peripheral T-cell and natural killer\/T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. The Lancet Regional Health - Western Pacific [Internet]. [cited 2025 July 11];10:100126. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666606521000353","DOI":"10.1016\/j.lanwpc.2021.100126"},{"key":"6782_CR2","doi-asserted-by":"crossref","unstructured":"Huang L, Yang Y, Zhao Z, Zhou S, Wu J, Wang N et al (2025) Clinical characteristics, treatment patterns, and survival outcomes of 1031 patients with peripheral T cell lymphoma in china: a multicenter, real-world study. Discov Onc [Internet] . [cited 2025 July 19]; 16(1). Available from: https:\/\/link.springer.com\/10.1007\/s12672-025-02980-8 \u00a0IF: 2.9 Q2 B4","DOI":"10.1007\/s12672-025-02980-8"},{"key":"6782_CR3","doi-asserted-by":"crossref","unstructured":"Shen Z, Hu L, Qiao J, Xu L, Xu K, Zhang H et al (2021) disparity analysis and prognostic value of pretreatment whole blood Epstein-Barr virus DNA load and EBER status in lymphomas: a retrospective multicenter study in huaihai lymphoma working group. Blood [Internet]. [cited 2025 July 11];138(Supplement 1):4570\u20134570. Available from: https:\/\/ashpublications.org\/blood\/article\/138\/Supplement%201\/4570\/477980\/Disparity-Analysis-and-Prognostic-Value-of","DOI":"10.1182\/blood-2021-149970"},{"key":"6782_CR4","doi-asserted-by":"crossref","unstructured":"Chen J, Zhou J, Cheng F, Chen D, Guan F, Zhang E et al (2024) Role of plasma EBV-DNA load and EBER status on newly diagnosed peripheral T-cell lymphoma. J Cancer Res Clin Oncol [Internet]. [cited 2025 July 11];150(4). Available from: https:\/\/link.springer.com\/10.1007\/s00432-024-05702-9 IF: 2.8 Q2 B4","DOI":"10.1007\/s00432-024-05702-9"},{"key":"6782_CR5","doi-asserted-by":"crossref","unstructured":"Nakamura N, Kanemura N, Matsumoto T, Nakamura H, Ikoma Y, Shibata Y et al (2023) Comparison of the prognostic impact of IPI and PIT in peripheral T-cell lymphoma in real-world practice with a large elderly population. Sci Rep [Internet]. [cited 2025 July 11];13(1). Available from: https:\/\/www.nature.com\/articles\/s41598-023-46501-5","DOI":"10.1038\/s41598-023-46501-5"},{"key":"6782_CR6","doi-asserted-by":"crossref","unstructured":"Gallamini A (2004) Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood [Internet]. Apr 1 [cited 2025 July 11];103(7):2474\u20132479. Available from: http:\/\/www.bloodjournal.org\/cgi\/doi\/10.1182\/blood-2003-09-3080 \u00a0IF: 23.1Q1 B1","DOI":"10.1182\/blood-2003-09-3080"},{"key":"6782_CR7","doi-asserted-by":"crossref","unstructured":"Van Der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM (2017) Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J [Internet]. [cited 2025 Oct 10];7(9):e603\u2013e603. Available from: https:\/\/www.nature.com\/articles\/bcj201785","DOI":"10.1038\/bcj.2017.85"},{"key":"6782_CR8","doi-asserted-by":"crossref","unstructured":"Sperling S, Fiedler P, Lechner M, Pollithy A, Ehrenberg S, Schiefer AI et al (2019) Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells. Blood [Internet]. [cited 2025 Oct 10];133(24):2597\u20132609. Available from: https:\/\/ashpublications.org\/blood\/article\/133\/24\/2597\/261462\/Chronic-CD30-signaling-in-B-cells-results-in","DOI":"10.1182\/blood.2018880138"},{"key":"6782_CR9","doi-asserted-by":"crossref","unstructured":"Han JJ, O\u2019byrne M, Stenson MJ, Maurer MJ, Wellik LE, Feldman AL et al (2018) Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma. Blood Cancer Journal [Internet]. [cited 2025 Oct 10];8(11):110. Available from: https:\/\/www.nature.com\/articles\/s41408-018-0138-8","DOI":"10.1038\/s41408-018-0138-8"},{"key":"6782_CR10","doi-asserted-by":"crossref","unstructured":"Janikova A, Michalka J, Chloupkova R, Kopalova N, Campr V, Kamaradova K et al (2022) Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL). Ann Hematol [Internet]. [cited 2025 Oct 10];101(4):789\u2013798. Available from: https:\/\/link.springer.com\/10.1007\/s00277-022-04759-1 \u00a0IF:\u00a02.4 Q2 B3","DOI":"10.1007\/s00277-022-04759-1"},{"key":"6782_CR11","unstructured":"Tournilhac O, Bouabdallah K Brentuximab Vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA Phase II Study"},{"key":"6782_CR12","doi-asserted-by":"crossref","unstructured":"Jiang XN, Yu BH, Yan WH, Lee J, Zhou XY, Li XQ (2020) Epstein\u2013Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture\/presentation and hijacked T-cell suppression. OncoImmunology [Internet]. [cited 2025 Oct 10];9(1):1683346. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/2162402X.2019.1683346 \u00a0IF: 6.3 Q1 B2","DOI":"10.1080\/2162402X.2019.1683346"},{"key":"6782_CR13","doi-asserted-by":"crossref","unstructured":"Witte HM, Merz H, Biersack H, Bernard V, Riecke A, Gebauer J et al (2020) Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr\u2010Virus positive diffuse large B cell lymphoma. Br J Haematol [Internet]. [cited 2025 Oct 10];189(2):257\u2013268. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.16342 \u00a0IF: 3.8 Q1 B2","DOI":"10.1111\/bjh.16342"},{"key":"6782_CR14","doi-asserted-by":"crossref","unstructured":"Wang WT, Xing TY, Du KX, Hua W, Guo JR, Duan ZW et al (2024) CD30 protects EBV-positive diffuse large B-cell lymphoma cells against mitochondrial dysfunction through BNIP3-mediated mitophagy. Cancer Letters [Internet].[cited 2025 Oct 10];583:216616. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524000107","DOI":"10.1016\/j.canlet.2024.216616"},{"key":"6782_CR15","doi-asserted-by":"crossref","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R et al (2019) Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. The Lancet [Internet]. [cited 2025 Oct 12];393(10168):229\u2013240. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673618329842","DOI":"10.1016\/S0140-6736(18)32984-2"},{"key":"6782_CR16","doi-asserted-by":"crossref","unstructured":"Carras S, Chartoire D, Mareschal S, Heiblig M, Mar\u00e7ais A, Robinot R et al (2021) Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming. Journal of Clinical Investigation [Internet]. [cited 2025 Oct 11];131(13):e139675. Available from: https:\/\/www.jci.org\/articles\/view\/139675","DOI":"10.1172\/JCI139675"},{"key":"6782_CR17","doi-asserted-by":"crossref","unstructured":"Yu F, Wang J, Ke Z, Zhang Y, Xu L, Zhang H et al (2024) EBV-positive Nodal T-Cell and NK-cell lymphoma: a study of 26 cases including a subset with strong CD30 expression mimicking anaplastic large cell lymphoma. American Journal of Surgical Pathology [Internet]. [cited 2025 Oct 11];48(4):406\u201316. Available from: https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002184 \u00a0IF: 4.2 Q1 B1","DOI":"10.1097\/PAS.0000000000002184"},{"key":"6782_CR18","doi-asserted-by":"crossref","unstructured":"Salas MQ, Climent F, Tapia G, DomingoDom\u00e8nech E, Mercadal S, Oliveira AC et al (2020) Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution. Biomarkers [Internet]. [cited 2025 Oct 11];25(1):69\u201375. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1354750X.2019.1691656 \u00a0IF: 1.9 Q3 B4","DOI":"10.1080\/1354750X.2019.1691656"},{"key":"6782_CR19","doi-asserted-by":"publisher","unstructured":"Li Z, Guo W, Bai O (2023) Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas. Front Oncol [Internet]. [cited 2025 Oct 11];13:1301437. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fonc.2023.1301437\/full","DOI":"10.3389\/fonc.2023.1301437\/full"},{"key":"6782_CR20","doi-asserted-by":"crossref","unstructured":"Gui L, Cao J, Ji D, Zhang H, Fan Q, Zhu J et al (2021) Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma. Chinese Journal of Cancer Research [Internet]. [cited 2025 Oct 11];33(5):616\u2013626. Available from: http:\/\/article.cjcrcn.org\/en\/article\/doi\/https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2021.05.08?viewType=HTML","DOI":"10.21147\/j.issn.1000-9604.2021.05.08"},{"key":"6782_CR21","doi-asserted-by":"crossref","unstructured":"Ji MM, Huang YH, Huang JY, Wang ZF, Fu D, Liu H et al (2018) Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. Haematologica [Internet]. [cited 2025 Oct 11];103(4):679\u2013687. Available from: http:\/\/www.haematologica.org\/lookup\/doi\/10.3324\/haematol.2017.182444 \u00a0IF: 7.9 Q1 B1","DOI":"10.3324\/haematol.2017.182444"},{"key":"6782_CR22","doi-asserted-by":"crossref","unstructured":"Huo YJ, Cheng S, Yi HM, Niu T, Fan L, Cui GH et al (2025) Molecular heterogeneity of CD30\u2009+\u2009peripheral T-cell lymphoma with prognostic significance and therapeutic implications: a retrospective multi-centre study. eBioMedicine [Internet]. [cited 2025 Oct 11];115:105693. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396425001379","DOI":"10.1016\/j.ebiom.2025.105693"},{"key":"6782_CR23","unstructured":"Herrera AF Brentuximab Vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by Brentuximab Vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study"},{"key":"6782_CR24","doi-asserted-by":"crossref","unstructured":"Prince HM, Hutchings M, Domingo-Domenech E, Eichenauer DA, Advani R (2023) Anti-CD30 antibody\u2013drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives. Ann Hematol [Internet]. [cited 2025 Oct 11];102(1):13\u201329. Available from: https:\/\/link.springer.com\/10.1007\/s00277-022-05054-9 \u00a0IF: 2.4 Q2 B3","DOI":"10.1007\/s00277-022-05054-9"},{"key":"6782_CR25","doi-asserted-by":"crossref","unstructured":"Jagadeesh D, Horwitz S, Bartlett NL, Kim Y, Jacobsen E, Duvic M et al (2022) Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma. The Oncologist [Internet]. [cited 2025 Oct 11];27(10):864\u2013873. Available from: https:\/\/academic.oup.com\/oncolo\/article\/27\/10\/864\/6659958","DOI":"10.1093\/oncolo\/oyac137"},{"key":"6782_CR26","doi-asserted-by":"crossref","unstructured":"Chen W, Zhang Z (2025) Recent advances in understanding the clinical responses of brentuximab vedotin in lymphoma and the correlation with CD30 expression. OTT [Internet]. [cited 2025 Oct 11];Volume 18:1\u201314. Available from: https:\/\/www.dovepress.com\/recent-advances-in-understanding-the-clinical-responses-of-brentuximab-peer-reviewed-fulltext-article-OTT","DOI":"10.2147\/OTT.S487088"},{"key":"6782_CR27","doi-asserted-by":"crossref","unstructured":"Wu Y, Chen D, Lu Y, Dong SC, Ma R, Tang W yan et al (2022) A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb. Cancer Gene Ther [Internet].[cited 2025 Oct 11];29(2):167\u2013177. Available from: https:\/\/www.nature.com\/articles\/s41417-021-00295-8","DOI":"10.1038\/s41417-021-00295-8"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06782-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06782-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06782-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:58:28Z","timestamp":1776405508000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06782-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6782"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06782-y","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethical Committee of each participating center and was conducted in accordance with the Declaration of Helsinki. On a voluntary participation basis, each patient had consented to the use of their clinical data and research findings for this study and academic publication. The study protocol was approved by the Ethics Committee of Guangdong Provincial People\u2019s Hospital (Approval No.: KY-Q-2021-225-02).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No Generative AI was used in the preparation of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI in scientific writing"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}